BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; ...

CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women ...

Tris Pharma Inc. can’t be sued by the state of Texas for manipulating test results on medication to treat minors for ...

Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX. Both companies have entered into an agreement for the global co-development and co-commercialization of ...

The Global Vaccine Storage Equipment Market is expected to grow at a rate of 8-10% by 2026. Rising number of infectious diseases and immunological disorders, large-scale implementation of vaccination ...

Dividend stocks are a smart way to navigate an uncertain market. Besides generating steady passive income, dividend-paying ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

The total potential value of the agreement, including development, regulatory, and commercial milestones, could reach $11.1 ...

By bolstering immune cells, researchers at ViiV Healthcare in Branford have designed long-acting drugs that prevent infection ...

Cold chain monitoring solutions have become indispensable to the biopharma business for managing complicated supply chains.

The market for drugs that encourage the immune system to attack tumors could explode in the next three years, leading Bristol ...